News | October 31, 2023
Alkem ‘Healthy Lungs' initiative aims to clear the air
The initiative will focus on advocating for cleaner air
The initiative will focus on advocating for cleaner air
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Investment is additive to KKR’s existing health care growth strategy
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Subscribe To Our Newsletter & Stay Updated
